Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with Curaderm<sup>BEC5</sup>

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.net/journal/jct
E-mail: [email protected]

Citations

Journals Menu

Guidelines & Policies

"Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with Curaderm^BEC5"
written by Bill E. Cham,
published by Journal of Cancer Therapy, Vol.4 No.2, 2013

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	The Value of Excipients and the Required Understanding of the Biological System in Product Development: An Impactful Example of Curaderm, a Topical Skin Cancer …
	International Journal of …, 2024

[2]	Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)?
	Journal of Cancer Therapy, 2024

[3]	Unique Clinical Features of Curaderm when Treating Skin Cancers
	Journal of Cancer Therapy, 2024

[4]	Holistic Approach in the Treatment of Actinic Keratosis: Benefits and Disadvantages of 5-Fluorouracil, Imiquimod, Diclofenac and Curaderm
	International Journal of Clinical Medicine, 2023

[5]	Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival
	2020

[6]	Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma
	2020

[7]	First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm: A Case Report
	2020

[8]	Outside the Box Cancer Therapies: Alternative Therapies That Treat and Prevent Cancer
	2019

[9]	Dangerous plants in dermatology: Legal and controlled
	Clinics in Dermatology, 2018

[10]	Outside the box cancer therapies : alternative therapies that treat and prevent cance
	2018

[11]	Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies
	2017

[12]	A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity. Relevance to BEC and Solamargine, Example of a …
	2015

[13]	A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical …
	2015

[14]	A standardized plant extract containing a target compound is acceptable as a potent therapeutic entity: Relevance to BEC and solamargine, a topical clinical …
	2015

[15]	Quantitative Sonography of Basal Cell Carcinoma
	Ultrasound in medicine & biology, 2015

[16]	A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation Curaderm BEC5
	Journal of Cancer Treatment and Research, 2015

[17]	Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities
	Journal of Cancer Therapy, 2015

[18]	A review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the penis.
	British Journal of Medicine and Medical Research, 2014

[19]	A review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the penis
	British Journal of Medicine and Medical Research, 2014

[20]	Statistics of envelope of ultrasonic backscatter from Basal Cell Carcinoma and Actinic Keratosis lesion
	Ultrasonics Symposium (IUS), 2014 IEEE International, 2014

[21]	Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes
	International Journal of Clinical Medicine, 2013

[22]	Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents
	2013

[23]	Topical Curaderm BEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes
	2013

[1]	Enhanced Analysis and Simplification of Scientific Findings with Emphasis on Katabasis and Anabasis on Safe and Effective Skin Cancer Treatment Using Curaderm Journal of Cancer Therapy, 2025 DOI:10.4236/jct.2025.164011

[2]	The Value of Excipients and the Required Understanding of the Biological System in Product Development: An Impactful Example of Curaderm, a Topical Skin Cancer Treatment International Journal of Clinical Medicine, 2024 DOI:10.4236/ijcm.2024.152005

[3]	Unique Clinical Features of Curaderm when Treating Skin Cancers Journal of Cancer Therapy, 2024 DOI:10.4236/jct.2024.151002

[4]	Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)? Journal of Cancer Therapy, 2024 DOI:10.4236/jct.2024.152004

[5]	Holistic Approach in the Treatment of Actinic Keratosis: Benefits and Disadvantages of 5-Fluorouracil, Imiquimod, Diclofenac and Curaderm International Journal of Clinical Medicine, 2023 DOI:10.4236/ijcm.2023.147027

[6]	First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm: A Case Report Journal of Cancer Therapy, 2020 DOI:10.4236/jct.2020.1110052

[7]	Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival Journal of Cancer Therapy, 2020 DOI:10.4236/jct.2020.118040

[8]	Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma International Journal of Clinical Medicine, 2020 DOI:10.4236/ijcm.2020.1110050

[9]	Dangerous Plants in Dermatology: Legal and Controlled Clinics in Dermatology, 2018 DOI:10.1016/j.clindermatol.2018.03.013

[10]	Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies International Journal of Clinical Medicine, 2017 DOI:10.4236/ijcm.2017.812064

[11]	Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities Journal of Cancer Therapy, 2015 DOI:10.4236/jct.2015.612114

[12]	Statistics of envelope of ultrasonic backscatter from Basal Cell Carcinoma and Actinic Keratosis lesion 2014 IEEE International Ultrasonics Symposium, 2014 DOI:10.1109/ULTSYM.2014.0474

[13]	Topical Curaderm^BEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes International Journal of Clinical Medicine, 2013 DOI:10.4236/ijcm.2013.45041

[14]	Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents Modern Chemotherapy, 2013 DOI:10.4236/mc.2013.22005

	[email protected]
	+86 18163351462 (WhatsApp)
	1655362766
	SCIRP WeChat

	[email protected]
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

Journal of Cancer Therapy

Journals Menu

Guidelines & Policies

Home

About SCIRP

Service

Policies